NEO adjuvant chemotherapy in breast cancer: What have we learned so far?
Nirmal V Raut1, Nilesh Chordiya
1Department of Medical Oncology, Terna Sahyadri Hospital, Nerul, Navi Mumbai, India.
Abstract:
Neoadjuvant chemotherapy (NACT) in breast cancer has undergone continuous evolution over the last few decades to establish its role in the combined modality management of these tumors. The process of evolution is still far from over. Many questions are still lurking in the minds of oncologists treating breast cancer. This review analyzes the evidence from metaanlyses, major multiinstitutional prospective trials, retrospective institutional series and systematic reviews in breast cancer to determine the current standards and controversies in NACT. The most effective drugs, their advantages, issues and controversies in delivery as well as the criteria for response are reviewed. A summary of evidence-based consensus is presented and unresolved aspects are discussed.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
